---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-22-000079"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:48:09.608693+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Vallon Pharma Q3 net loss $1.0M; cash $5.2M; strategic review ongoing

## Summary
- Net loss of $1.0M for Q3 2022; R&D expenses reversed to $(18,000) vs $0.2M in Q3 2021.
- G&A expenses $1.4M, up from $1.0M, driven by $0.6M in strategic evaluation costs.
- Cash, cash equivalents and marketable securities of $5.2M as of Sept 30, 2022.
- Strategic alternatives review with Ladenburg Thalmann remains ongoing; no transaction guaranteed.

## SEC filing metadata
- accession: 0001824293-22-000079
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/0001824293-22-000079-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/ck00018242493-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-22-000079
- JSON: https://secwatch.observer/filing/0001824293-22-000079.json
- Plain text: https://secwatch.observer/filing/0001824293-22-000079.txt

## Key facts
- Earnings Releases
  GRI Bio, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 3, 2022, Vallon Pharmaceuticals, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824293/000182429322000079/0001824293-22-000079-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.